K2M Group Holdings Inc. (NASDAQ:KTWO) rose 1% during mid-day trading on Tuesday . The company traded as high as $18.13 and last traded at $17.34, with a volume of 242,887 shares changing hands. The stock had previously closed at $17.17.

KTWO has been the subject of a number of research reports. Piper Jaffray Cos. reaffirmed a “buy” rating on shares of K2M Group Holdings in a research note on Saturday, April 2nd. JMP Securities initiated coverage on shares of K2M Group Holdings in a research note on Friday, April 8th. They issued an “outperform” rating and a $25.00 price objective for the company. Northland Securities cut shares of K2M Group Holdings from an “outperform” rating to a “market perform” rating in a research note on Tuesday, May 3rd. Needham & Company LLC reaffirmed a “buy” rating and issued a $21.00 price objective on shares of K2M Group Holdings in a research note on Tuesday, May 3rd. Finally, Zacks Investment Research cut shares of K2M Group Holdings from a “hold” rating to a “sell” rating in a research note on Wednesday, May 4th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $22.00.

The stock’s market capitalization is $734.28 million. The firm’s 50 day moving average is $15.57 and its 200 day moving average is $14.20.

K2M Group Holdings (NASDAQ:KTWO) last issued its quarterly earnings results on Monday, May 2nd. The medical device company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.23) by $0.02. The business had revenue of $56.20 million for the quarter, compared to analyst estimates of $56 million. During the same quarter in the prior year, the company earned ($0.37) earnings per share. K2M Group Holdings’s quarterly revenue was up 11.7% on a year-over-year basis. Equities analysts expect that K2M Group Holdings Inc. will post ($1.10) earnings per share for the current fiscal year.

In other news, CFO Gregory S. Cole sold 6,465 shares of K2M Group Holdings stock in a transaction that occurred on Saturday, May 21st. The shares were sold at an average price of $11.32, for a total transaction of $73,183.80. Following the sale, the chief financial officer now owns 33,233 shares in the company, valued at $376,197.56. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Carlos A. Ferrer acquired 20,000 shares of K2M Group Holdings stock in a transaction dated Thursday, May 5th. The shares were bought at an average price of $11.32 per share, for a total transaction of $226,400.00. Following the transaction, the director now owns 59,382 shares of the company’s stock, valued at $672,204.24. The disclosure for this purchase can be found here.

Other large investors recently added to or reduced their stakes in the company. Nationwide Fund Advisors boosted its stake in K2M Group Holdings by 3.8% in the fourth quarter. Nationwide Fund Advisors now owns 98,318 shares of the medical device company’s stock valued at $1,941,000 after buying an additional 3,597 shares during the last quarter. New York State Common Retirement Fund boosted its stake in K2M Group Holdings by 1.6% in the fourth quarter. New York State Common Retirement Fund now owns 141,690 shares of the medical device company’s stock valued at $2,797,000 after buying an additional 2,170 shares during the last quarter. Paradigm Capital Management Inc. NY boosted its stake in K2M Group Holdings by 625.2% in the fourth quarter. Paradigm Capital Management Inc. NY now owns 169,700 shares of the medical device company’s stock valued at $3,350,000 after buying an additional 146,300 shares during the last quarter. Principal Financial Group Inc. boosted its stake in K2M Group Holdings by 1.3% in the fourth quarter. Principal Financial Group Inc. now owns 398,277 shares of the medical device company’s stock valued at $7,862,000 after buying an additional 5,127 shares during the last quarter. Finally, OppenheimerFunds Inc. boosted its stake in K2M Group Holdings by 13.1% in the fourth quarter. OppenheimerFunds Inc. now owns 908,054 shares of the medical device company’s stock valued at $17,925,000 after buying an additional 105,014 shares during the last quarter.

K2M Group Holdings, Inc is a medical device company focused on designing, developing and commercializing spine technologies and techniques. The Company’s spine products are used by spine surgeons to treat spinal pathologies, such as deformity (primarily scoliosis), trauma and tumor. The Company is engaged in designing, development and commercialization of products for patients suffering from degenerative spinal conditions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.